Ply Chichareon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4143849/publications.pdf

Version: 2024-02-01

567281 345221 1,376 47 15 36 citations h-index g-index papers 47 47 47 1858 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
2	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. European Heart Journal, 2018, 39, 3314-3321.	2.2	116
3	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 2019, 40, 2595-2604.	2.2	93
4	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. Frontiers in Cardiovascular Medicine, 2020, 7, 119.	2.4	65
5	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
6	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. JACC: Cardiovascular Interventions, 2019, 12, 259-270.	2.9	46
7	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis, 2020, 295, 45-53.	0.8	36
8	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery forÂLeftÂMainÂDisease. Journal of the American College of Cardiology, 2019, 73, 1877-1886.	2.8	33
9	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2572-2584.	2.8	31
10	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. European Heart Journal, 2018, 39, 3381-3389.	2.2	29
11	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Expert Review of Medical Devices, 2019, 16, 211-228.	2.8	27
12	Impact of postâ€procedural minimal stent area on 2â€year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26
13	Efficacy and Safety of TicagrelorÂMonotherapy in PatientsÂUndergoing Multivessel PCI. Journal of the American College of Cardiology, 2019, 74, 2015-2027.	2.8	23
14	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
15	DAPT Score and the Impact of TicagrelorÂMonotherapy During the Second Year After PCI. JACC: Cardiovascular Interventions, 2020, 13, 634-646.	2.9	17
16	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e539-e546.	3.2	16
17	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e1090-e1098.	3.2	16
18	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. Thrombosis and Haemostasis, 2020, 120, 1087-1095.	3.4	14

#	Article	IF	CITATIONS
19	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	3.3	14
20	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020, 109, 1125-1139.	3.3	14
21	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	2.2	11
22	Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. European Journal of Cardio-thoracic Surgery, 2019, 57, 676-683.	1.4	10
23	Post-implantation shear stress assessment: an emerging tool for differentiation of bioresorbable scaffolds. International Journal of Cardiovascular Imaging, 2019, 35, 409-418.	1.5	10
24	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	3.0	10
25	A comparison of ventricular systolic function indices provided by VolumeView/EV1000â,,¢ and left ventricular ejection fraction by echocardiography among septic shock patients. Journal of Clinical Monitoring and Computing, 2019, 33, 233-239.	1.6	7
26	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7
27	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
28	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and Cardiovascular Interventions, 2020, 96, 1369-1378.	1.7	6
29	Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry. Journal of Clinical Medicine, 2020, 9, 2713.	2.4	6
30	Twilight, the Dawn of a New Era of Aspirin-Free PCI?. Journal of the American College of Cardiology, 2020, 75, 2425-2429.	2.8	6
31	Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 569-578.	1.7	6
32	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
33	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 16, 634-644.	3.2	6
34	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). American Journal of Cardiology, 2019, 124, 1833-1840.	1.6	5
35	The impact of plaque type on strut embedment/protrusion and shear stress distribution in bioresorbable scaffold. European Heart Journal Cardiovascular Imaging, 2020, 21, 454-462.	1.2	5
36	Application of the MADS classification system in a "mega mammoth―stent trial: Feasibility and preliminary clinical implications. Catheterization and Cardiovascular Interventions, 2019, 93, 57-63.	1.7	5

#	Article	IF	CITATIONS
37	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	1.7	5
38	Prevalence and predictors associated with in-hospital mortality in acute ST segment elevation myocardial infarction after reperfusion therapy in developing country. Cardiovascular Diagnosis and Therapy, 2020, 10, 1264-1269.	1.7	4
39	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	1.7	4
40	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
41	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
42	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Canadian Journal of Cardiology, 2020, 36, 747-755.	1.7	2
43	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. Circulation Journal, 2019, 83, 556-566.	1.6	1
44	Two years clinical outcomes with the stateâ€ofâ€theâ€art PCI for the treatment of bifurcation lesions: A subâ€analysis of the SYNTAX II study. Catheterization and Cardiovascular Interventions, 2020, 96, 10-17.	1.7	1
45	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. Atherosclerosis, 2020, 303, 1-7.	0.8	1
46	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	0
47	Predicting mortality in cardiac care unit patients: external validation of the Mayo cardiac intensive care unit admission risk score. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1065-1073.	1.0	O